source
- Lilly buys another pain biotech; FDA sets decision for once-weekly PrEP pillPlus, news about Merck, MultiValent Biotherapies, Alvotech, enGene, Mirum, and Adaptive Biotechnologies. 💸 Eli Lilly acquires another pain biotech: The Indianapolis pharma giant has made its 11th…Endpoints · 1mo ago↗ source
- Edgewise heart drug passes key trial testStill, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy medicines from Bristol Myers Squibb and Cytokinetics.BioPharma Dive · 1mo ago↗ source
- Neumora depression drug fails; EnGene to cut 50% of staffNeumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.